Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Evelo Biosciences Inc (EVLO)

Evelo Biosciences Inc (EVLO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 98,264
  • Shares Outstanding, K 107,994
  • Annual Sales, $ 0 K
  • Annual Income, $ -122,180 K
  • 60-Month Beta 1.31
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 9.89
Trade EVLO with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.24
  • Most Recent Earnings -0.28 on 11/14/22
  • Next Earnings Date 03/23/23
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 330.85% ( -432.93%)
  • Historical Volatility 121.19%
  • IV Percentile 86%
  • IV Rank 42.42%
  • IV High 778.71% on 12/27/22
  • IV Low 0.92% on 08/19/22
  • Put/Call Vol Ratio 1.20
  • Today's Volume 22
  • Volume Avg (30-Day) 321
  • Put/Call OI Ratio 9.95
  • Today's Open Interest 3,133
  • Open Int (30-Day) 3,886

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.30
  • Number of Estimates 3
  • High Estimate -0.28
  • Low Estimate -0.33
  • Prior Year -0.54
  • Growth Rate Est. (year over year) +44.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7400 +22.96%
on 02/01/23
1.5600 -41.67%
on 01/04/23
-0.6601 (-42.04%)
since 01/03/23
3-Month
0.7400 +22.96%
on 02/01/23
2.4000 -62.09%
on 11/16/22
-1.2201 (-57.28%)
since 11/03/22
52-Week
0.7400 +22.96%
on 02/01/23
4.6000 -80.22%
on 02/07/22
-3.4901 (-79.32%)
since 02/03/22

Most Recent Stories

More News
Horizon Technology Finance Provides Fourth Quarter 2022 Portfolio Update

/PRNewswire/ -- Horizon Technology Finance Corporation (NASDAQ: HRZN) ("HRZN" or the "Company"), a leading specialty finance company that provides capital in...

HRZN : 12.31 (-0.65%)
EVLO : 0.9099 (+6.43%)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Evelo Biosciences, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

/PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of...

EVLO : 0.9099 (+6.43%)
Cellarity Announces Close of $121 Million Series C Financing

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the completion of a $121 million Series C financing, bringing its total funding...

DNLI : 31.70 (-2.97%)
EVLO : 0.9099 (+6.43%)
FHTX : 8.39 (-1.87%)
MRNA : 173.25 (-1.76%)
OMGA : 7.22 (-8.14%)
RUBY : 0.2784 (-5.27%)
SANA : 4.68 (-4.88%)
MCRB : 5.50 (-3.00%)
Cellarity Releases Novel, Open-Source, Single-Cell Dataset and Invites the Machine Learning and Computational Biology Communities to Develop New Algorithms Capable of Learning Fundamental Rules of Cell Behavior

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the release of a unique single-cell dataset to accelerate innovation in mapping...

DNLI : 31.70 (-2.97%)
EVLO : 0.9099 (+6.43%)
FHTX : 8.39 (-1.87%)
MRNA : 173.25 (-1.76%)
OMGA : 7.22 (-8.14%)
RUBY : 0.2784 (-5.27%)
SANA : 4.68 (-4.88%)
MCRB : 5.50 (-3.00%)
Evelo Biosciences, Inc. (EVLO) Q2 2022 Earnings Call Transcript

EVLO earnings call for the period ending June 30, 2022.

EVLO : 0.9099 (+6.43%)
Evelo Biosciences Announces Succession Plan

– Simba Gill to transition to Chair of the Board of Directors –– Lord Ara Darzi will become Lead Independent Director –– Board has retained Spencer Stuart...

EVLO : 0.9099 (+6.43%)
Evelo Biosciences Announces Second Quarter 2022 Financial Results and Business Highlights

– Health authority feedback on registration trials for EDP1815 in psoriasis expected by year-end –– Two Phase 2 clinical read-outs with EDP1815 in atopic...

EVLO : 0.9099 (+6.43%)
Evelo Biosciences to Announce Second Quarter 2022 Financial Results on Thursday, August 11, 2022

CAMBRIDGE, Mass., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel...

EVLO : 0.9099 (+6.43%)
Evelo Biosciences Announces Appointment of Marella Thorell as Chief Financial Officer

CAMBRIDGE, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel...

EVLO : 0.9099 (+6.43%)
Michael Severino, M.D., Joins Flagship Pioneering-Founded Tessera Therapeutics as Chief Executive Officer

Flagship Pioneering, the bioplatform innovation company, and Tessera Therapeutics, the biotechnology company pioneering GENE WRITING technology, today announced that Michael Severino, M.D., has joined...

DNLI : 31.70 (-2.97%)
EVLO : 0.9099 (+6.43%)
FHTX : 8.39 (-1.87%)
MRNA : 173.25 (-1.76%)
OMGA : 7.22 (-8.14%)
RUBY : 0.2784 (-5.27%)
SANA : 4.68 (-4.88%)
MCRB : 5.50 (-3.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Evelo Biosciences, Inc. operates as a bio-technology company. It develops therapies for the treatment of the gut-body network. The company also offers treatment for cancer and inflammatory diseases. Its product portfolio consists of EDP1066 which are in clinical stage. Evelo Biosciences is based in Massachusetts,...

See More

Key Turning Points

3rd Resistance Point 1.0808
2nd Resistance Point 1.0146
1st Resistance Point 0.9623
Last Price 0.9099
1st Support Level 0.8438
2nd Support Level 0.7776
3rd Support Level 0.7253

See More

52-Week High 4.6000
Fibonacci 61.8% 3.1255
Fibonacci 50% 2.6700
Fibonacci 38.2% 2.2145
Last Price 0.9099
52-Week Low 0.7400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar